Abstract
Fifteen patients with breast cancer and skeletal metastases who had bone pain refractory to opioid analgesics and who were not eligible for or had not responded to local field radiotherapy, were treated with strontium-89. All patients had received previous treatment with chemotherapy and radiotherapy for bone metastases. Severity of bone pain, sleeping pattern, mobility and dependency on analgesics were evaluated before and 4, 8 and 12 weeks after89Sr administration. Patients received 2 MBq/kg (118–148 MBq) of89Sr by i.v. injection. Pain relief and a reduction in analgesic requirements were observed in 7 of the 15 (47%) patients, with a reduction in the severity score from 34% to 71%. Duration of the response varied from 3 to 7 months. A decrease in peripheral blood cell count was observed in 11 patients: a 15%–66% reduction in white cell count and a 14%–75% reduction in platelet count were detected at 12 weeks after treatment in these patients. We conclude that89Sr is effective (47% response rate) for bone pain palliation in patients with bone metastases from breast cancer. Dependency on opioid analgesics may be reduced in patients with refractory bone pain.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Malawer MM, Delaney TE Treatment of metastatic cancer to bone. In: De Vita VT, Hellman S, Rosenberg S, eds.Cancer. Principles and practice of oncology. Philaldelphia: J.B. Lippincott; 1993: 2225–2245.
Aziz H, Choi K, Sohn C. Comparison of32p therapy and sequential hemibody irradiation (HBI) for bony metastases as methods of whole body irradiation.Am J Clin Oncol 1986; 9: 264–268.
Pecher C. Biological investigations with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in treatment of metastatic bone cancer.University of California Publications Pharmacol 1942; 2: 117–149.
Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan JB, Macleod PM, Zivanovic MA. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.Br J Radiol 1991; 64: 816–822.
Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA. A prospective randomised double blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone.Eur J Cancer 1991; 27: 954–958.
Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana, Yakemchuk VN, Thomas GM, Erlich LE, Crook J, Gulenchyn KY, Hong KE, Wesolowski C, Yardley J. Results of a randomised phase-III trial to evalulate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.Int J Radiat Oncol Biol Phys 1993; 25: 805–813.
Robinson RG. Strontium 89 precursor targeted therapy for pain relief of blastic metastatic disease.Cancer 1993; 72 (11-Suppl): 3433–3434.
Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, Reed NSE, Russell JM, Yardley J. A comparison of the palliative effects of strontium 89 and external beam radiotherapy in metastatic prostate cancer.Radiother Oncol 1994; 31: 33–40.
Guirrieri P, Modoni S, Parisi S, Fusco V, Oriolo V, Rendina G, Paleani-Vettori PG. Bone formation markers and pain palliation in bone metastases treated with strontium 89.Am J Oncol 1994; 17: 77–79.
Robinson RG, Preston DF, Baxter KG, Dusing RW, Spicer JA. Clinical experience with strontium 89 in prostatic and breast cancer patients.Semin Oncol 1993; 20 (Suppl 2): 44–48.
Chammas S, Esche BA, Reid R, Gulenchyn K, Crook J. Strontium 89 for palliation of bone metastases from carcinoma of breast.Clin Invest Med 1992; 15 (4 Suppl): A134.
Silberstein EB. The treatment of painful osseous metastases with phosphorus-32-labeled phosphates.Semin Oncol 1993; 20 (Suppl 2): 10–21.
Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Strontium-89 therapy: strontium kinetics in disseminated carcinoma of the prostate.Eur J Nucl Med 1986; 12: 447–454.
Blake GM, Zivanovic MA, Lewington VJ. Measurements of the strontium plasma clearance rate in patients receiving 89-Sr radionuclide therapy.Eur J Nucl Med 1989; 15: 780–783.
Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.J Nucl Med 1988; 29: 549–557.
Breen SL, Powe JE, Porter AT. Dose estimation in strontium 89 radiotherapy of metastatic prostate cancer.J Nucl Med 1992; 33: 1316–1323.
Robinson RG. Systemic radioisotope therapy of primary and metastatic bone cancer.J Nucl Med 1990; 31: 1326–1327.
McEwan AJ, Amyotte GA, McGowan DG, MacGillivray JA, Porter AT. A retrospective analysis of the cost effectiveness of treatment with Melastron (89Sr-chloride) in patients with prostate cancer metastatic to bone.Nucl Med Commun 1994: 15: 499–504.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berna, L., Carrio, I., Alonso, C. et al. Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain. Eur J Nucl Med 22, 1101–1104 (1995). https://doi.org/10.1007/BF00800589
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00800589